Page Title
Drug Development Pipeline
LAU-7b
Status
Phase TwoTherapeutic Approach
Anti-Inflammatory
LAU-7b is an oral compound. It is a form of the retinoid fenretinide. Retinoids are a group of compounds related to vitamin A. LAU-7b was studied for its potential to reduce the inflammatory response in the lungs of people with CF.
Status
A phase 2 study to test the safety and effectiveness of LAU-7b in people with CF was completed.
Sponsor
This program is sponsored by Laurent Pharmaceuticals. It was conducted within the Therapeutics Development Network.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More